197 related articles for article (PubMed ID: 37091176)
1. An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies.
Khan S; Allsup D; Molica S
Front Oncol; 2023; 13():1135812. PubMed ID: 37091176
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
5. Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia.
Spaner DE; Venema R; Huang J; Norris P; Lazarus A; Wang G; Shi Y
EBioMedicine; 2018 Sep; 35():222-232. PubMed ID: 30174282
[TBL] [Abstract][Full Text] [Related]
6. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of IgA- and/or IgG-switched chronic lymphocytic leukemia B cells.
Matolcsy A; Casali P; Nádor RG; Liu YF; Knowles DM
Blood; 1997 Mar; 89(5):1732-9. PubMed ID: 9057657
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia.
Colado A; Elías EE; Sarapura Martínez VJ; Cordini G; Morande P; Bezares F; Giordano M; Gamberale R; Borge M
Sci Rep; 2021 Jun; 11(1):12926. PubMed ID: 34155276
[TBL] [Abstract][Full Text] [Related]
9. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia.
Scrivener S; Goddard RV; Kaminski ER; Prentice AG
Leuk Lymphoma; 2003 Mar; 44(3):383-9. PubMed ID: 12688308
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections.
Link H; Kerkmann M; Holtmann L; ;
Support Care Cancer; 2022 Jun; 30(6):5187-5200. PubMed ID: 35257229
[TBL] [Abstract][Full Text] [Related]
11. IgG+, CD5+ human chronic lymphocytic leukemia B cells. Production of IgG antibodies that exhibit diminished autoreactivity and IgG subclass skewing.
Wakai M; Hashimoto S; Omata M; Sthoeger ZM; Allen SL; Lichtman SM; Schulman P; Vinciguerra VP; Diamond B; Dono M
Autoimmunity; 1994; 19(1):39-48. PubMed ID: 7538331
[TBL] [Abstract][Full Text] [Related]
12. B-chronic lymphocytic leukemia cells contain both endogenous kappa immunoglobulin mRNA and critical immunoglobulin gene activation transcription factors.
Zaknoen SL; Christian SL; Suen R; Van Ness B; Kay NE
Leukemia; 1992 Jul; 6(7):675-9. PubMed ID: 1625486
[TBL] [Abstract][Full Text] [Related]
13. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia.
Potter KN; Mockridge CI; Neville L; Wheatley I; Schenk M; Orchard J; Duncombe AS; Packham G; Stevenson FK
Clin Cancer Res; 2006 Mar; 12(6):1672-9. PubMed ID: 16551848
[TBL] [Abstract][Full Text] [Related]
15. Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia.
Humphries LA; Godbersen JC; Danilova OV; Kaur P; Christensen BC; Danilov AV
Br J Haematol; 2013 Dec; 163(5):590-602. PubMed ID: 24117128
[TBL] [Abstract][Full Text] [Related]
16. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
Front Immunol; 2020; 11():594556. PubMed ID: 33312177
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia.
Svensson T; Höglund M; Cherif H
Scand J Infect Dis; 2013 Jul; 45(7):537-42. PubMed ID: 23427875
[TBL] [Abstract][Full Text] [Related]
18. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.
Parikh SA; Leis JF; Chaffee KG; Call TG; Hanson CA; Ding W; Chanan-Khan AA; Bowen D; Conte M; Schwager S; Slager SL; Van Dyke DL; Jelinek DF; Kay NE; Shanafelt TD
Cancer; 2015 Sep; 121(17):2883-91. PubMed ID: 25931291
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia.
Freeman JA; Crassini KR; Best OG; Forsyth CJ; Mackinlay NJ; Han P; Stevenson W; Mulligan SP
Leuk Lymphoma; 2013 Jan; 54(1):99-104. PubMed ID: 22738394
[TBL] [Abstract][Full Text] [Related]
20. Structural aspects of human IgM antibodies expressed in chronic B lymphocytic leukemia.
Ramsland PA; Brock CR; Moses J; Robinson BG; Edmundson AB; Raison RL
Immunotechnology; 1999 Mar; 4(3-4):217-29. PubMed ID: 10231091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
